Resumen
Doxorubicin (ADRIAMYCIN, RUBEX) is a chemotherapeutic agent that is commonly administered to breast cancer patients in standard chemotherapy regimens. As true of all such therapeutic cytotoxic agents, it can damage normal, noncancerous cells and might affect biochemical processes in a manner that might lead to, or contribute to, chemotherapy-induced cognitive deficits when administered either alone or in combination with other agents.
| Idioma original | English |
|---|---|
| Título de la publicación alojada | Chemo Fog |
| Subtítulo de la publicación alojada | Cancer Chemotherapy-Related Cognitive Impairment |
| Editores | Robert Raffa, Ronald Tallarida |
| Páginas | 147-156 |
| Número de páginas | 10 |
| DOI | |
| Estado | Published - 2010 |
Serie de la publicación
| Nombre | Advances in Experimental Medicine and Biology |
|---|---|
| Volumen | 678 |
| ISSN (versión impresa) | 0065-2598 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
Huella
Profundice en los temas de investigación de 'Chemo Brain (Chemo Fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver